Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 25;19(1):21.
doi: 10.1186/s12981-022-00447-2.

Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana

Stephen Opoku  1   2 , Samuel Asamoah Sakyi  3 , Nana Kwame Ayisi-Boateng  4 , Anthony Kwame Enimil  5 , Ebenezer Senu  6   3 , Richard Owusu Ansah  6 , Bismark Dankwah Aning  6 , Diana Atsieno Ojuang  6 , Doreen Nafula Wekesa  6 , Fatima Osman Ahmed  6 , Chidinma B Okeke  6 , Ama Darkoaa Sarfo  5
Affiliations
Review

Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana

Stephen Opoku et al. AIDS Res Ther. .

Abstract

Background: Viral suppression remains the most desired outcome in the management of patients with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) and this can be achieved by an effective Antiretroviral Therapy (ART). However, some patients who achieve viral suppression may experience viral rebound with dire consequence. We evaluated viral suppression and rebound and their associated factors among adult patients on ART in Kumasi, Ghana.

Methods: This hospital-based retrospective study was conducted at the Komfo Anokye Teaching Hospital in Ghana. We reviewed the medical records of 720 HIV patients on ART. Statistical analyses were performed using SPSS Version 26.0 and GraphPad prism version 8.0. p < 0.05 was considered statistically significant.

Results: Proportions of patients with viral suppression and viral rebound were 76.1% and 21.0% respectively. Being diagnosed at WHO stage I [aOR = 11.40, 95% CI (3.54-36.74), p < 0.0001], having good adherence to ART [aOR = 5.09, 95% CI (2.67-9.73), p < 0.0001], taking Nevirapine-based regimen [aOR = 4.66, 95% CI (1.20-18.04), p = 0.0260] and increasing duration of treatment (p < 0.0001) were independently associated with higher odds of viral suppression. However, being diagnosed at WHO stage II (aOR = 7.39, 95% CI 2.67-20.51; p < 0.0001) and stage III (aOR = 8.62, 95% CI 3.16-23.50; p < 0.0001), having poor adherence (aOR = 175.48, 95% CI 44.30-695.07; p < 0.0001), recording baseline suppression value of 20-49 copies/mL (aOR = 6.43, 95% CI 2.72-15.17; p < 0.0001) and being treated with Zidovudine/Lamivudine/Efavirenz (aOR = 6.49, 95% CI 1.85-22.79; p = 0.004) and Zidovudine/Lamivudine/Nevirapine (aOR = 18.68, 95% CI 1.58-220.90; p = 0.02) were independently associated with higher odds of viral rebound.

Conclusion: Approximately 76% viral suppression rate among HIV patients on ART in Kumasi falls below the WHO 95% target by the year 2030. Choice of ART combination, drug adherence, WHO clinical staging and baseline viral load are factors associated with suppression or rebound. These clinical characteristics of HIV patients must be monitored concurrently with the viral load.

Keywords: Antiretroviral therapy (ART); HIV/AIDS; Viral rebound; Viral suppression.

PubMed Disclaimer

Conflict of interest statement

Authors have declared that no competing interests exist.

Figures

Fig. 1
Fig. 1
Consort flow chart
Fig. 2
Fig. 2
Viral suppression (A) and rebound (B) among HIV patients on treatment
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):1005–70. doi: 10.1016/S0140-6736(14)60844-8. - DOI - PMC - PubMed
    1. Wang H, Wolock TM, Carter A, Nguyen G, Kyu HH, Gakidou E, et al. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV. 2016;3(8):e361–e87. doi: 10.1016/S2352-3018(16)30087-X. - DOI - PMC - PubMed
    1. HIVAIDS . JUNPo. Report on the global acquired immunodeficiency syndrome epidemic. Geneva: UNAIDS; 2008.
    1. GhanaAIDS. 2019 HIV Sentinel Survey Report. Ghana AIDS Commission; 2019.
    1. Jamieson D, Kellerman SE. The 90 90 90 strategy to end the HIV Pandemic by 2030: can the supply chain handle it? J Int AIDS Soc. 2016;19(1):20917. doi: 10.7448/IAS.19.1.20917. - DOI - PMC - PubMed